What increasing confidence in Biogen's latest Alzheimer's drug means for Eli Lilly

Eli Lilly's (LLY) Alzheimer's efforts are not central to our investment case, but Biogen's (BIIB) full trial data is incrementally positive.

from Top News and Analysis (pro) https://ift.tt/1SUHdbM